Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,671 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07230639RecruitingPhase 2
Shorter radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a shorter course of radiation combined with chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07622797RecruitingPhase 2
Immunotherapy with chemotherapy and radiation for esophageal cancer
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
Luoyang, HenanAges 18 years+ - NCT06543069RecruitingPhase 2
Combination therapy for unresectable peritoneal mesothelioma
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
BeijingAges 18 years+ - NCT06534190RecruitingPhase 2
PET scan to guide immunotherapy in advanced solid tumors
This trial uses a special PET scan to see how immune cells (CD8 T cells) are working in your tumor before you start a PD-1 immunotherapy drug (nivolumab or cetrelimab). The goal is to find out if the scan can predict whether the immunotherapy will work for you.
AmsterdamAges 18 years+ - NCT06587425RecruitingPhase 2
Combination therapy for CLDN18.2-positive advanced stomach cancer
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06730386RecruitingPhase 1
Trial of AK138D1 for advanced solid tumors
This trial tests a new drug called AK138D1 for people with advanced solid tumors that have not responded to or can't tolerate standard treatments. The goal is to see if it is safe and effective.
Blacktown, New South WalesAges 18–75 - NCT06764355RecruitingPhase 2
Chemo, Immunotherapy, and Chemoradiation Before Surgery for Advanced Esophageal Cancer
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
TaipeiAges 18–75 - NCT07448077RecruitingPhase 2
Short radiation with immunotherapy for rectal cancer
This trial tests a combination of short-course radiation, chemotherapy, and an immunotherapy drug (Enlonstobart) for patients with a specific type of rectal cancer called pMMR. It aims to see if this approach can shrink tumors before surgery and improve outcomes.
Shijiazhuang, HebeiAges 18 years+ - NCT06468358RecruitingPhase 1/Phase 2
LB1410 and LB4330 for advanced solid tumors
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75 - NCT06956248Recruiting
Access to new treatments for advanced solid tumors
This trial offers access to experimental or non-standard cancer treatments for people with advanced solid tumors who have run out of standard options. The goal is to find new ways to treat cancers that are hard to manage.
SingaporeAges 21–99 - NCT07266298RecruitingPhase 1
T-cell therapy for advanced solid tumors
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
Beijing, Beijing MunicipalityAges 18–75 - NCT07283367RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
GuangzhouAges 18 years+ - NCT06132828RecruitingPhase 1
Testing DR30206 for advanced or metastatic solid tumors
This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05536128RecruitingPhase 2
Fulvestrant plus DNA damage drugs after CDK4/6 treatment failure
This Phase 2 trial studies whether combining fulvestrant with medicines that block DNA repair can help treat HR+/HER2- metastatic or inoperable breast cancer that has progressed after endocrine therapy plus a CDK4/6 inhibitor. It also aims to check the safety of this combination and see if it can control the cancer for longer.
SeoulAges 19 years+ - NCT06196697RecruitingPhase 2
New immunotherapy combo for advanced stomach cancer
This clinical trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus chemotherapy as the first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if this combination helps control the cancer better than standard therapy.
HarbinAges 18–75 - NCT06826313RecruitingPhase 1
Virus treatment for advanced solid tumors
This trial tests an intravenous virus treatment (VRT106) for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if the virus can target and help control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07281326RecruitingPhase 1
A study of AK138D1 for advanced solid tumors
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
Harbin, HeilongjiangAges 18–75 - NCT06798376Recruiting
Immunotherapy plus chemo before stomach cancer surgery
This trial tests combining immunotherapy (PD-1 blockers) with chemotherapy before surgery for advanced stomach cancer. The goal is to find the best number of treatment cycles to shrink the tumor and improve surgery results.
BeijingAges 18–90 - NCT07289997RecruitingPhase 2
Combination therapy for advanced AFP-producing gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
Shijiazhuang, HebeiAges 18 years+ - NCT06055738RecruitingPhase 2
Zimberelimab with chemo before surgery for cervical cancer
This trial tests a combination of immunotherapy (zimberelimab) and chemotherapy before surgery for locally advanced cervical cancer that has not spread far. It aims to shrink the tumor to make surgery more effective.
Xi'an, ShaanxiAges 18 years+ - NCT05385861Enrolling by invitationPhase 1/Phase 2
ONIVYDE plus carboplatin for advanced gut neuroendocrine cancer
This Phase 1/2 study tests ONIVYDE® (a type of irinotecan drug) combined with carboplatin in people with advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma. The goal is to see how well the treatment works and how safely it can be given.
Kaohsiung CityAges 20–80 - NCT07007273RecruitingPhase 2
Pembrolizumab for advanced skin sarcomas (not angiosarcoma)
This trial is testing a drug called pembrolizumab (Keytruda) for people with advanced soft tissue sarcomas that started in the skin. The goal is to see if this immunotherapy can help shrink or slow the growth of these tumors.
Tampa, FloridaAges 18 years+ - NCT06627634Recruiting
Surgery for stomach cancer that spread to the liver
This trial tests if removing the stomach tumor and liver spots together can help people with stomach cancer that has spread only to the liver. It is for those who are healthy enough for surgery and chemotherapy.
Aarhus, JyllandAges 18 years+
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,671 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.